ArticleBritish journal of haematology2026

The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.

Rory M Shallis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.